Menu ×

HEALTHCARE & PHARMACEUTICAL

Buprenorphine Market Segmentation by Route of Administration (Sublingual, Transdermal, and Buccal); by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Buprenorphine Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

·    June 2021: Purdue Pharma LP announced that FDA accepted and filing of the abbreviated new drug application for vial dosage form of nalmefene hydrochloride injection, which is designed to treat opioid overdose.

·    May 2020: Hikma Pharmaceuticals PLC launched Buprenorphine Hydrochloride Injection, 0.3mg/mL in the United States through its American affiliate

Buprenorphine Market Highlights 2022 – 2030

The buprenorphine market is estimated to garner a large revenue by growing at a CAGR of ~14% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the growing prevalence of chronic pain disorders, increasing occurrence of cancer. According to the World Health Organization (WHO), cancer is the leading cause of deaths worldwide, accounting to about 10 million deaths in the year 2020. In addition to these, escalating government investments in healthcare in developed nations and rising usage of buprenorphine patches as an effective treatment mode is also anticipated to drive market growth in the coming years. Furthermore, the growing dependency on painkillers has led to opioid addiction to many people around the world, which in turn is projected to provide lucrative opportunities to significantly raise the demand for buprenorphine in the near future.

Buprenorphine Market

The market is segmented by route of administration into sublingual, transdermal, and buccal, out of which, the sublingual segment is anticipated to hold the largest share in the buprenorphine market on account of the increasing availability of buprenorphine drugs in several dosages in the sublingual form. Along with this, rapid drug absorption, first-pass metabolism and quick onset of action of sublingual route of administration are also predicted to boost the growth of the market segment in the forecast period. Additionally, the segment for buccal dosage is expected to witness notable growth in the future, which can be credited to the increasing number of people opting for oral drugs as compared to injection-based drugs. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Buprenorphine Market Regional Synopsis

On the basis of geographical analysis, the buprenorphine market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is estimated to grab the largest market share over the forecast period on the back of the strong presence of market players and growing percentage of the population suffering from opioid dependency in the region. As per the data by National Institute of Drug Abuse, 21 to 29 percent of patients misuse the opioids prescribed for chronic pain. Amongst these, 8-12% people develop an opioid use disorder. Apart from these, high number of cases of abuse related to drugs such as heroin and cocaine is also anticipated to drive the region’s market growth in the forthcoming years. Europe is also expected to acquire a notable share in the market owing to the large number of new medical product launches in the region. Moreover, the market in Asia Pacific is projected to witness noteworthy growth during the forecast period ascribing to the rising patient pool and growing awareness about the health benefits of buprenorphine in the region.

Global Buprenorphine Market

The buprenorphine market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the buprenorphine market includes the following segments:

By Route Of Administration

  • Sublingual
  • Transdermal
  • Buccal

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Growth Drivers

  • Increasing Occurrence of Chronic Pain Disorders
  • Rising Healthcare Expenditure in Developed Nations

Challenges

  • Adverse Health Effects Associated with the Use of Buprenorphine

Top Featured Companies Dominating the Market

  • The Siegfried Group, LLP
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Johnson Matthey Group
  • Purdue Pharma LP
  • Pharmaforce Inc.
  • Hikma Pharmaceuticals PLC
  • Bedford Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • Neon Laboratories Ltd.
  • Unichem Laboratories

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved